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The work carried out under this contract consisted of two indepen-
dent but closely related tasks designed to implement the Manned Space-
craft Center's programs concerned with the application of EEG and EEG
analysis to the study of sleep-wake cycles in man.
TASK I
This study was designed to evaluate analytic EEG computer pro-
grams developed by the Neurophysiology Group at Baylor/Methodist to
extract information not available through standardized visual (clinical)
reading of the analog trace, or to provide quantitative information con-
cerning the analog trace which can only be characterized in subjective,
non-numerical terms by visual analysis (see Carrie and Frost, 1971).
A small general-purpose computer system for EEG wavelength-amplitude
profile analysis, developed with the support of a previous contract for
the Manned Spacecraft Center (NAS 9-9418), was employed for the anal-
ysis of tapes that were developed for inclusion in the NASA/Baylor
Normative EEG Library. These tapes were developed for the unique
purpose of making a quantitative analysis of changes elicited in the
electroencephalograms of young male adults by a drug known to produce
subtle EEG changes in therapeutic doses.
Because sleep-promoting drugs are carried in space missions
for emergency use, it was decided that the agent to be utilized should
be of this character. The agent selected, flurazepam hydrochloride
(a benzodiazepine derivative), was chosen because it has been
demonstrated to be a clinically useful hypnotic agent (Jick, 1969; Kales
et al. , 1969) that promotes sleep without excessively suppressing the
REM stage, as do other hypnotics. Also, other benzodiazepine deriv-
atives such as chlordiazepoxide and diazepam had been shown to pro-
duce fairly marked and consistent EEG changes in therapeutic doses
(Lairy, 1962; Towler et al. , 1962). Preliminary visual analysis of
the EEGs of patients receiving flurazepam hydrochloride had shown
that similar EEG changes were induced by this derivative also.
Method
Subjects. Five male, volunteer subjects were selected on the
basis of interviews and screening tests to participate in the study. All
subjects were free of known major medical or psychiatric disorders,
had received no medication during the preceding 30-day period, and
presented normal screening EEG evaluations.
Procedure. On the day after the routine clinical EEG screening
test, the EEG of each subject was recorded at 90-minute intervals over
a period of 8 hours to establish his usual waking pattern (baseline test).
During recording, subjects were at rest with eyes closed, at rest with
eyes open, and provided 3 minutes of voluntary overventilation. After
the baseline test, each subject received 30 mg of flurazepam hydro-
chloride nightly for 2 weeks, after which a placebo was substituted for
a second 2-week period. An 8-hour test similar to the baseline study
was performed weekly, and a single clinical EEG test was run every
other day. In two subjects who showed some residual effects at the
end of the 2 weeks of placebo administration, a final 8-hour test was
carried out after a third week, during which neither drug nor placebo
was administered.
Only one of the investigators knew whether drug or placebo was
being administered. The subjects were not told the name of the drug
that was under evaluation until the end of the project.
Visual EEG interpretation. The EEG records for each 8-hour
test and for each of the intervening shorter tests were interpreted
visually by a clinical electroencephalographer. Each record was exam-
ined individually to detect the presence of any EEG change or any
unusual or abnormal electrographic event. The amount of fast (beta)
activity that was present in each recording was rated according to an
arbitrary scale.
EEG recording and quantification. EEGs were obtained with a
Beckman Type R electroencephalograph and were recorded simultan-
eously on analog magnetic tape to permit off-line computer analysis.
EEG signals were quantified by a modified version of the system
described by Carrie and Frost (1971). The outputs from 2 EEG chan-
nels were subjected simultaneously to bandpass filtering (Krohn-Hite
333B filters) in order to limit the range of EEG frequencies contained
in the signals. The settings on the filters were adjusted in separate
analysis runs to give essentially flat responses between 3 c/sec and
7 c/sec (theta range), 6 c/sec and 14 c/sec (alpha range), and 14 c/sec
and 38 c/sec (beta range) with a relatively high degree of attenuation
of frequencies above and below these range limits. The filtered signals
were then analyzed with a LINC-8 computer during each analysis run
in real time. Consecutive waves in each of the filtered signals were
sorted automatically into 60 different wavelength categories in each
band. The limits of the passbands defined by the digital programs were
136.07 and 370.46 msec (theta range), 55.99 and 173.18 msec (alpha
range), and 77. 04 and 24. 96 msec (beta range).
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In 2 subjects, 1000 consecutive waves in the alpha range were
acquired from each channel during each analysis run. In the other
3 subjects, the analysis time for alpha was 100 seconds. The analysis
time for all subjects was 100 seconds for theta and 30 seconds for beta.
Alpha and theta activity in the C-^-O^ and 04-02 derivations and beta
activity in the F,-C3 and ^2-0^ derivatives were quantified. During
the recording of the EEG for alpha and theta analysis, the subjects
closed their eyes; samples for beta analysis were obtained under both
the "eyes-closed" and the "eyes-open1/ conditions. The digital computer
counted the number of waves in each of the 60 wavelength categories;
the summated peak-to-peak amplitude in each wavelength category also
was computed. Following the acquisition of this information in real
time, 14 measurements and statistical variables that described quanti-
tatively the characteristics of the EEG signal were calculated for each
channel. Three of these measurements were used in this study for the
examination of the effects of the drug on the EEG.
Additional quantitative analysis was performed using an IBM
360/50 computer (see Results).
R e suit s
Visual analysis
No consistent change was detected in alpha or theta activity
throughout the study in any of the subjects.
Visual examination showed an increase in the amplitude of beta
activity in the EEGs of all the subjects during administration of the
drug. This increase was rated as "minimal" in 2 subjects, "very
slight" in one, "clear-cut" in one, and "very pronounced" in one. No
other changes consistently associated with drug administration were
reported by the electroencephalographer.
One subject showed episodes of 14 and 6/sec positive spikes in
the majority of his records. The same subject showed bursts of gen-
eralized "abortive" spike and wave patterns which were not present in
the baseline recording but which were maximal in amplitude and fre-
quency of occurrence at 2 and 3 weeks after withdrawal of the drug.
,'
Computer analysis
Graphic plots. The mean wavelength, the average wave
amplitude, and the number of waves during the fixed analysis time were
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each plotted as a function of test days. Examination of these plots sup-
ported the results of visual interpretation of the EEG tracings in that
no changes in the alpha and beta activity that were associated consis-
tently with the administration of the drug could be defined. However,
in all 5 subjects there was a clearly detectable change in fast, or beta,
activity during the period of flurazepam administration. This change
was characterized by an increase in the number of waves in the 30-second
epoch during which the EEG was analyzed. There was a less definite
increase in average wave amplitude with no detectable change in mean
wavelength. The change in beta activity was most striking during
periods when the subjects' eyes were open. There was a considerable
degree of variability in the magnitude and persistence of the EEG
response to drug administration. In 3 subjects, the EEG returned to
the starting level within 2 weeks of drug withdrawal. The other 2 sub-
jects showed a relatively marked change in beta activity during drug
administration, and 3 weeks elapsed before restoration of the baseline
pattern occurred. The findings from one subject, which are typical of
those from the whole group, are shown in Fig. 1.
Statistical analysis
An IBM 360/50 computer was used via a remote access statistical
system to obtain a quantitative assessment of the information displayed
in the graphic plots of beta activity. The significance of the difference
between scores obtained during the baseline 8-hour test and each of the
other 8-hour tests was calculated for each subject. In 2 subjects, 12
samples of EEG were obtained from each channel during an 8-hour test
for beta analysis; in the other 3 subjects, the 8-hour tests yielded 24
samples for beta analysis. It was found that most of the scores
obtained during drug administration, and also some of the scores
obtained 2 and 3 weeks after drug withdrawal, differed from the base-
line observations beyond the 5% level of significance.
In order to detect changes consistently related to administration
of the drug, the results for all 5 subjects for both sides were pooled
for each EEG variable and for each test. The number of tests showing
P values of more than 0.05, and the numbers showing P values of less
than 0.05 for increases and decreases in the variables as compared
with the 8-hour baseline levels, were determined using the Wilcoxon
matched-pairs signed-ranks test (Siegel, 1956). The results are dis-
played in the form of a. series of block histograms in Fig. 2. The most
consistently significant change from the baseline that was related to
drug administration was an increase in the number of beta waves during
the analysis epoch, with a less consistent tendency for the wave ampli-
tude to increase.
5.
Discussion
In this investigation, visual evaluation of EEG records indicated
that administration of flurazepam hydrochloride was associated with an
increase in the prominence of relatively high frequency components of
the signal. This type of EEG change is also often caused by other
widely used benzodiazepine derivatives, such as chlordiazepoxide
(Kaim and Rosenstein, I960; Winfield and Aivazian, 1961; Lairy, 1962;
Geissman et al. , 1962) and diazepam (Towler et al., 1962; Requin et
aL, 1963)..
The results of computer analysis confirmed the findings obtained
by visual analysis and also demonstrated an aspect of the drug effect
that was not obvious on visual inspection of the original EEG tracings.
It was found that the increase in the prominence of beta activity was
characterized mainly by a consistent increase in the incidence of waves
in the 14-38 c/sec range with a much less consistent increase in their
average amplitude and with no detectable change in average wavelength
(frequency).
Although the most consistent changes in EEG characteristics were
associated with flurazepam administration, some significant differences
were detected by the highly sensitive techniques used in this study
between the baseline measurements and those obtained up to 3 weeks
after withdrawal of the drug. This finding may have been the result of
an inadequate baseline measurement, or of normal temporal variability
in EEG characteristics as measured by the technique used in this study,
or of real drug effects that persisted for at least 3 weeks after with-
drawal. Further investigation will be required before any conclusions
can be drawn.
Summary
A computer-analysis technique was used to evaluate the changes
in the waking EEGs of 5 normal subjects which occurred during the oral
administration of flurazepam hydrochloride (Dalmane). While the sub-
jects were receiving the drug, there was an increase in the amount of
beta (14-38 c/sec) activity in fronto-central EEG leads in all 5 subjects.
This increase in beta activity was characterized by a highly consistent
increase in the number of waves that occurred during an EEG recording
interval of fixed duration and by a less consistent increase in average
wave amplitude. There was no detectable change in mean EEC wave-
length (frequency) within the beta frequency range. The EEG patterns
reverted to their baseline condition during 2-3 weeks after withdrawal
of the drug.
Analysis of the alpha, theta and delta components of the EEG
indicated no changes during or following administration of the drug.
This study clearly illustrates the usefulness of specific computer-
analysis techniques in the characterization and quantification of sleep-
promoting drugs upon the EEG of the normal young adults in the waking
state. The influence of such drugs in modifying the stages of sleep has
been well established, but no quantitative studies have yet been made
of the effects of such drugs upon the wave components of the various
sleep stages.
The 33 tapes used in this study have been entered and inventoried
as a permanent part of the Normative EEG Library.
TASK II
This task consisted of the fabrication for DB4 MSC certain items
of EEG sleep-monitoring and analysis equipment developed by the
Neurophysiology Group at Baylor/Methodist. These items are unique
in that they represent the products of applied research carried out by
the Neurophysiology Group over a period of several years and are
prototypes basic to anticipated flight-hard ware development for a
proposed Skylab I sleep-monitoring experiment.
t
Fabricated and delivered to DB4 MSC were two preamplifiers
and 150 EEG monitoring caps with electrodes. These conformed to the
specifications outlined in the final report to NASA of Contract NAS 9-10747
under which these items were finally developed.
FIGURE LEGENDS
Fig. 1. Three measurements of EEG characteristics plotted as a
function of test days. The thicker bars on the time axis indicate
that relevant points are the averages of measurements obtained
during an 8-hour test. There is a clear-cut increase in the number
of waves in the 14-38 c/sec band, with a much less definite increase
in average wave amplitude, during drug administration.
Fig. 2. Each block histogram shows pooled results from all 5 subjects
and both sides of the head for each 8-hour test. The number of
tests giving P values (Wilcoxon matched-pairs signed-ranks test)
of less than 0. 05 for increases or decreases in the measurements
as compared with the 8-hour baseline levels, or P values of more
than 0.05 (N. S.) are shown. The most consistent drug-related
change was an increase in the number of waves during an EEG
recording interval of fixed duration, with a less definite increase
in average wave amplitude.
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APPENDIX
The alpha-analysis program, IA and IB, and examples of II, a
wavecount/wavelength profile, III, a summated peak-peak amplitude/
wavelength profile and IV, mean-wave amplitude /wavelength profile
from a single electrode pair on the left side of the head.
IA
ALPHA ANALYSIS/LEFT
SUMMATED PEAK/PEAK AMPLITUDES
DURING DATA ACQUISITION 15287 MICROVOLTS
MEAN WAVE AMPLITUDE/WAVELENGTH
PROFILE ANALYSIS...
WAVELENGTH OF WAVES WITH
LARGEST MEAN AMPLITUDES 0096 MILLISECS
LARGEST MEAN AMPLITUDE= 0020.2 MICROVOLTS
MEAN= 0102 MILLISECS
VARIANCE= 0786 MILLISECS
STANDARD DEVIATION 0028 MILLISECS ;
MEDIAN= 0094 MILLISECS
INTEH-QUARTILE RANGE= 0028 MILLISECS
WAVECOUNT/WAVELENGTH
PROFILE ANALYSIS...
WAVECOUNT AT MODAL WAVELENGTH= 0126 WAVES
MODAL WAVELENGTH= 0086 MILLISECS
MEAN= 0088 MILLISECS
VARIANCE= 0133 MILLISECS
STANDARD DEVIATIONS 0012 MILLISECS
MEDIAN= 0084 MILLISECS
INTER-QUARTILE RANGE= 0008 MILLISECS
ANALYSIS TIME= 0090 SECS
AVERAGE WAVE AMPLITUDES 0015.3 MICROVOLTS
IB
ANALYSIS OPTIONS...
SELECT DESIRED OPTION:
1 NAME
2 BLOCK NO.
2
ENTER DESIRED BLOCK NUMBER:
120
SELECT ANALYSIS REQUIRED:
1 ALPHA
2 BETA
3 THETA
1
SELECT DESIRED SIDE:
1 LEFT SIDE
2 RIGHT SIDE
3 BOTH SIDES
1
STATISTICAL MEASURES REQUIRED:
1 ALL MEASURES
2 SOME MEASURES
1
SELECT DESIRED OPTION:
1 CALIBRATION FACTOR
2 SCALING FACTOR
3 BOTH FACTORS
4 NEITHER FACTOR
1
ENTER CALIBRATION FACTOR:
1 .7
.SELECT DESIRED OPTION:
1 DETAILED PRINT-OUT
2 QUICK PRINT-OUT
1 '
BLOCK NO. 120
OPTION NO. 3
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